Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG for Cerebral and Retinal Amyloid in MCI due to AD
NCT03319810Phase 2Completed
- Sponsor
- Sutter Health
- Start
- Jan 2018
- Primary completion
- Jul 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of intravenous immunoglobulin G in Alzheimer's disease (AD), sponsored by Sutter Health. Started Jan 2018; status: completed.
02
Drugs
intravenous immunoglobulin G
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03319810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03319810.